Celularity (NASDAQ:CELU) Trading 0.7% Higher

Celularity Inc. (NASDAQ:CELUGet Free Report)’s share price traded up 0.7% on Monday . The stock traded as high as $3.28 and last traded at $3.07. 30,203 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 157,223 shares. The stock had previously closed at $3.05.

Celularity Stock Performance

The company has a 50 day simple moving average of $3.17 and a 200 day simple moving average of $3.58.

Hedge Funds Weigh In On Celularity

A hedge fund recently bought a new stake in Celularity stock. Keynote Financial Services LLC bought a new stake in shares of Celularity Inc. (NASDAQ:CELUFree Report) during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 15,566 shares of the company’s stock, valued at approximately $81,000. Keynote Financial Services LLC owned about 0.08% of Celularity as of its most recent filing with the SEC. 19.02% of the stock is currently owned by institutional investors.

Celularity Company Profile

(Get Free Report)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

Featured Articles

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.